A drug that can prevent people from contracting HIV will receive funding from Pharmac.
Pre-exposure prophylaxis (PrEP) is a medication that can reduce users’ risk of contacting the HIV virus by more than 90 percent.
Pharmac announced on Wednesday that it will fund PrEP under the brand name Truvada from March 1. The pill is a combination of anti-viral drugs emtricitabine and tenofovir disoproxil fumarate, and is designed to be taken daily.
New Zealand will be one of the first countries in the world to publicly fund PrEP for HIV prevention, which was one of the Labour Party’s election promises.
To read the complete article click here